Lanier’s study [ 19 ] indicated some improvement in Pediatric Asthma Quality of Life Questionnaire and nocturnal asthma symptom scores in both groups, with a slightly greater change observed in the omalizumab group; however, these differences did not reach statistical significance.
← all excerpts
Safety and efficacy of omalizumab in children aged 6 to 11 years with asthma: a systematic review and meta-analysis of randomized controlled trials.
1
—
—